Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Nonalcoholic Fatty Liver Disease
NCT07900087Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 3 trial of roflumilast in non-alcoholic fatty liver disease (NAFLD), sponsored by Tanta University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
roflumilast
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07900087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900087.